Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
Public ClinicalTrials.gov record NCT01191801. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
Study identification
- NCT ID
- NCT01191801
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sunesis Pharmaceuticals
- Industry
- Enrollment
- 711 participants
Conditions and interventions
Conditions
Interventions
- placebo + cytarabine Drug
- vosaroxin + cytarabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2010
- Primary completion
- Sep 25, 2014
- Completion
- Feb 28, 2017
- Last update posted
- Aug 21, 2018
2010 – 2017
United States locations
- U.S. sites
- 38
- U.S. states
- 20
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores UCSD Cancer Center | La Jolla | California | 92093 | — |
| UCLA Division of Hematology/Oncology | Los Angeles | California | 90095 | — |
| Sharp Clinical Oncology Research | San Diego | California | 92123 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| HCA HealthONE - Rocky Mountain Blood and Marrow Transplant Program | Denver | Colorado | 80218 | — |
| George Washington University-Medical Faculty Associates | Washington D.C. | District of Columbia | 20037 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Baptist Cancer Institute | Jacksonville | Florida | 32207 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Georgia Health Sciences University | Augusta | Georgia | 30912 | — |
| Rush University Medical Center, Division of Hematology/Oncology | Chicago | Illinois | 60612 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| St. Francis Medical Group Oncology and Hematology Specialists | Indianapolis | Indiana | 46237 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Ellis Fischel Cancer Center, University of Missouri Health Care | Columbia | Missouri | 65203 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| North Shore Long Island Jewish Health System | Lake Success | New York | 11042 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 100065 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794 | — |
| New York Medical College, Division of Oncology/Hematology | Valhalla | New York | 10595 | — |
| Mecklenburg Medical Group | Charlotte | North Carolina | 28204 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| University Hospitals fo Cleveland | Cleveland | Ohio | 44106 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Family Cancer Center | Memphis | Tennessee | 38119 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Henry-Joyce Cancer Clinic | Nashville | Tennessee | 37232 | — |
| UT Southwestern Medical Center at Dallas | Dallas | Texas | 75390 | — |
| The University of Texas, M.D. Anderson Cancer Center, Department of Leukemia | Houston | Texas | 77030 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78229 | — |
| Department of Medicine Section of Hematology/Oncology, West Virginia University Hospitals, Mary Babb Randolph Cancer Center, West Virginia University | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01191801, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2018 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01191801 live on ClinicalTrials.gov.